Indivior PLC
INDV
Company Profile
Business description
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Contact
10710 Midlothian Turnpike
Suite 125
North Chesterfield
RichmondVA23235
USAT: +1 804 379-1090
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,164
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,297.04 | 247.18 | -0.58% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,198.96 | 111.83 | -0.58% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,850.25 | 31.38 | -0.53% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |